Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P13671
UPID:
CO6_HUMAN
Alternative names:
-
Alternative UPACC:
P13671
Background:
Complement component C6 is a crucial part of the membrane attack complex (MAC), which plays a pivotal role in both innate and adaptive immunity by forming pores in the plasma membrane of target cells. This action is fundamental in the body's defense mechanism against pathogens.
Therapeutic significance:
Complement component 6 deficiency is a rare condition that results in increased susceptibility to severe recurrent infections, especially by Neisseria gonorrhoeae or Neisseria meningitidis. Understanding the role of Complement component C6 could open doors to potential therapeutic strategies, particularly in enhancing immune response and preventing infections.